GO:0106089 negative regulation of cell adhesion involved in sprouting angiogenesis

Sprouting angiogenesis is the process by which new blood vessels emerge from pre-existing vasculature, and it requires tightly controlled endothelial cell adhesion to the extracellular matrix and to neighboring cells. GO:0106089, negative regulation of cell adhesion involved in sprouting angiogenesis, defines the biological process that stops, prevents or reduces the frequency, rate or extent of cell adhesion specifically during sprouting angiogenesis. This term captures a critical braking mechanism that ensures vessel sprouting is not excessive or disorganized. Researchers study GO:0106089 because it sits at the intersection of vascular biology, extracellular matrix signaling and cancer progression. For example, extracellular matrix-bound angiopoietin-like 4 (ANGPTL4) inhibits endothelial cell adhesion, migration and sprouting, and alters the actin cytoskeleton, directly exemplifying this negative regulation. In parallel, integrin alpha-v-beta-8 has been identified as a negative regulator of tumor angiogenesis in a mosaic mouse model of astrocytoma, demonstrating that this process can suppress pathological vessel formation. Understanding GO:0106089 is therefore essential for dissecting how tissues control angiogenesis, how tumors evade or exploit vascular remodeling, and how therapeutic strategies might modulate endothelial adhesion to normalize or starve aberrant vessels. This article integrates the QuickGO definition with real PubMed literature to provide a research-grade overview of the genes, mechanisms and experimental models relevant to this term.

GO:0106089 is a biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of cell adhesion involved in sprouting angiogenesis. In other words, it encompasses molecular and cellular events that actively suppress the adhesion of endothelial cells to the extracellular matrix or to each other during the formation of new vessel sprouts. This negative regulation is essential for proper vascular morphogenesis and for preventing pathological angiogenesis.

GO:0106089 is important because it provides a molecular brake on angiogenesis, a process that must be tightly controlled to maintain tissue homeostasis and to prevent diseases such as cancer, retinopathies and chronic inflammation. Without negative regulation of cell adhesion during sprouting, endothelial cells could adhere excessively or inappropriately, leading to disorganized vessel networks and pathological angiogenesis. Studying this term helps researchers identify therapeutic targets that can either promote or inhibit vessel growth in a context-dependent manner.

The following genes and proteins have been experimentally linked to negative regulation of cell adhesion involved in sprouting angiogenesis, based on the verified literature.

The process of negative regulation of cell adhesion involved in sprouting angiogenesis is itself regulated by extracellular matrix composition and bioavailability of anti-adhesive factors such as ANGPTL4. Integrin expression levels, particularly alpha-v-beta-8, modulate the extent of negative regulation in tumor angiogenesis. Additionally, cytoskeletal regulators such as Rho GTPases may influence the stability of adhesions and thus the efficacy of negative regulation. However, specific upstream regulators like mTOR or ISR have not been directly implicated in the verified citations for this term, so they are not discussed here.

Integrin alpha-v-beta-8 acts as a negative regulator of tumor angiogenesis in astrocytoma, and its loss leads to increased vessel formation. This links GO:0106089 directly to cancer progression, where uncontrolled angiogenesis supports tumor growth. ANGPTL4 also inhibits endothelial sprouting, suggesting that its dysregulation could contribute to tumor vascularization.

Excessive or insufficient negative regulation of endothelial adhesion during sprouting could contribute to vascular malformations or retinopathies, although direct evidence from the verified citations is limited to cancer models. The balance between pro- and anti-adhesive signals is critical for normal vessel development.

In vitro sprouting assays, such as the aortic ring or spheroid sprouting assay, can measure the effect of negative regulators like ANGPTL4 on endothelial cell adhesion and sprout formation. These assays allow quantification of sprout number and length under controlled conditions.

Cell adhesion assays using extracellular matrix-coated plates can directly measure the ability of endothelial cells to adhere in the presence or absence of negative regulators. Such assays are useful for testing ANGPTL4 and integrin function.

Fluorescence microscopy of actin filaments (e.g., phalloidin staining) can reveal cytoskeletal changes induced by negative regulators of adhesion. This method helps visualize how ANGPTL4 alters the actin cytoskeleton.

Mosaic mouse models of astrocytoma can assess the role of integrins in tumor angiogenesis. These models allow conditional deletion or overexpression of candidate genes in the tumor microenvironment.

Researchers studying negative regulation of cell adhesion involved in sprouting angiogenesis-related genes often need to determine whether a candidate gene is causally involved in suppressing endothelial adhesion and sprouting. EDITGENE provides a comprehensive suite of CRISPR services to enable such causal studies, from knockout to knock-in and overexpression models, as well as library screening and bioinformatics support.

GO:0106089, negative regulation of cell adhesion involved in sprouting angiogenesis, represents a critical braking mechanism in vascular biology. Key regulators such as ANGPTL4 and integrin alpha-v-beta-8 have been experimentally shown to inhibit endothelial adhesion and sprouting, with direct implications for tumor angiogenesis. Understanding this process offers opportunities for therapeutic intervention in cancer and other angiogenesis-dependent diseases. CRISPR-based models from EDITGENE can accelerate causal discovery and validation of genes within this pathway.